Phase 1 × Completed × Lymphoma, T-Cell, Cutaneous × Clear all Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Phase 1 Completed
16 enrolled
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
Phase 1 Completed
20 enrolled
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Phase 1 Completed
56 enrolled
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1 Completed
5 enrolled
MNA-D
Phase 1 Completed
20 enrolled
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Phase 1 Completed
106 enrolled
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1 Completed
16 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1 Completed
286 enrolled 26 charts
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Phase 1 Completed
8 enrolled 18 charts
EpiBrentlen
Phase 1 Completed
6 enrolled
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Phase 1 Completed
11 enrolled 16 charts
20139157 T-VEC
Phase 1 Completed
26 enrolled
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Phase 1 Completed
5 enrolled
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Phase 1 Completed
44 enrolled
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Phase 1 Completed
66 enrolled
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Phase 1 Completed
24 enrolled
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
24 enrolled
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Phase 1 Completed
58 enrolled 15 charts
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
55 enrolled
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
34 enrolled
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase 1 Completed
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
23 enrolled 9 charts
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 1 Completed
11 enrolled 10 charts
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Phase 1 Completed
43 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Phase 1 Completed
70 enrolled
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase 1 Completed
44 enrolled
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Phase 1 Completed
86 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
PI3K
Phase 1 Completed
35 enrolled
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1 Completed
20 enrolled
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Phase 1 Completed
18 enrolled 7 charts
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
20 enrolled
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Depsipeptide in Treating Patients With Solid Tumors
Phase 1 Completed
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed